Macrophage infiltration into the subendothelial space at lesion prone sites is the primary event in atherogenesis. Inhibition of macrophage homing might therefore prevent atherosclerosis. Since HDL levels are inversely correlated with cardiovascular risk, their effect on macrophage homing was assessed in apoE-deficient (apoE ؊/؊ ) mice. Overexpression of human apolipoprotein AI in apoE ؊/؊ mice increased HDL levels 3-fold and reduced macrophage accumulation in an established assay of leukocyte homing to aortic root endothelium 3.2-fold (P<0.005). This was due to reduced in vivo ␤VLDL oxidation, reduced ␤VLDL triggered endothelial cytosolic Ca 2؉ signaling through PAF-like bioactivity, lower ICAM-1 and VCAM-1 expression, and diminished ex vivo leukocyte adhesion. Adenoviral gene transfer of human PAF-acetylhydrolase (PAF-AH) in apoE ؊/؊ mice increased PAF-AH activity 1.5-fold (P<0.001), reduced ␤VLDL-induced ex vivo macrophage adhesion 3.5-fold (P<0.01), and reduced in vivo macrophage homing 2.6-fold (P<0.02). These inhibitory effects were observed in the absence of increased HDL cholesterol levels. In conclusion, HDL reduces macrophage homing to endothelium by reducing oxidative stress via its associated PAF-AH activity. This protective mechanism is independent of the function of HDL as cholesterol acceptor. Modulation of lipoprotein oxidation by PAF-AH may prevent leukocyte recruitment to the vessel wall, a key feature in atherogenesis.-Theil-
Serum high density lipoprotein cholesterol (HDL-C) independently predicts coronary artery disease (1) . It correlates inversely with restenosis after coronary angioplasty (2) . Even small increments of HDL-C protect against cardiovascular disease (3) . Transgenic expression of apolipoprotein AI (apo AI) increases HDL and delays atherosclerosis (4 -6) .
HDL may exert its protective effect by functioning as a cholesterol acceptor in reverse cholesterol transport (7) or by reducing leukocyte/endothelial cell interactions. The latter effect has been attributed to suppression of endothelial cytokine-induced vascular cell adhesion molecule 1 (VCAM-1) expression (8) or to protection of low density lipoprotein (LDL) from oxidative modification, possibly mediated by HDL-associated paraoxonase (9) and platelet-activating factor acetylhydrolase (PAF-AH) (10) . We have recently shown that oxidized LDL (oxLDL) predicts the risk for cardiovascular disease in humans. Ox-LDL levels were inversely related to HDL cholesterol levels (11) . Oxidation of the phospholipid content of LDL generates compounds with PAF-like bioactivity (10) . These substances, in vitro, induce expression of the adhesion molecules VCAM-1 and intercellular adhesion molecule 1 (ICAM-1) on the endothelial cell surface. The transcriptional activation is partially due to rises of cytosolic Ca 2ϩ (12) . Adhesion molecule expression depends on NFB and can be prevented in vitro by antioxidants (13) , HDL and PAF-AH (14, 15) .
In the present study the effect of HDL on endothelial cell/leukocyte interaction was evaluated in apoE Ϫ/Ϫ mice using the macrophage homing assay of Patel et al. (16) . The beneficial effect of high levels of HDL is explained by an attenuation of oxidative stress and decreased endothelial adhesiveness in vivo. Human PAF-AH gene transfer studies reveal the antioxidative capacity of PAF-AH as an active principle for the antiatherogenic effect of HDL and suggest a potential gene therapy approach for atherosclerosis.
MATERIALS AND METHODS

Animals
ApoE
Ϫ/Ϫ mice (17) were backcrossed for 10 generations into the C57BL/6 background. Human apo AI transgenic mice (4) in the C57BL/6 apoE Ϫ/Ϫ background have been described elsewhere (6) . Groups were of mixed but matched gender and fed regular mouse chow; macrophage donors were 8 wk old C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine). The Institutional Research Animal Care Committee approved all animal procedures.
Macrophage homing assay
Macrophages were isolated, labeled, and injected as described (16) . ICAM-1 and VCAM-1 blocking studies in vivo were carried out with monoclonal antibodies (mAb) 3E21 (18) and 429 (19) . Hamster immunoglobulin G (IgG) mAb G235-2356 or R35-95 rat IgG 2a served as corresponding isotype controls (PharMingen, San Diego, Calif.). The antibodies (100 g) were injected intraperitoneally (i.p.) 6 h prior to macrophages.
After 4 days, blood was drawn from barbiturate anesthetized mice in 0.1 vol of 0.1 M citrate/1 mM EDTA/10 M butylated hydroxytoluene/20 M vitamin E. Mice were perfused with 0.9% saline/1 U/ml heparin. Thoracic aortas were dissected and snap frozen for RNA isolation. Heart base and ascending aorta were OCT embedded, stored at Ϫ80°C, and cryosectioned at 7 m. Macrophages phagocytosed between 1 and 10 microspheres and were counted in fluorescent light as single or groups of microspheres that were associated with a macrophage adherent to the aortic wall. Macrophages were counted in 140 serial sections per mouse, spanning the proximal 1 mm of the aortic valve region. After intravenous (i.v.) injection in apoE Ϫ/Ϫ mice, numbers of homing macrophages were 353 Ϯ 85 at 24 h, 259 Ϯ 159 at 48 h, 235 Ϯ 37 after 96 h, and 316 Ϯ 132 after 8 days (nϭ6, 8, 13, 3, Pϭns) . Aortic lesion areas were assessed on oil red O-stained sections. The macrophage specific antibody MAC3 (PharMingen) was used to stain and detect areas occupied by macrophages with the Quantimet 600 image analyzer (Leica, Brussels, Belgium).
Flow chamber experiments
Monolayers of fEnd.5 (20) grown on collagen-coated glass coverslips were mounted in a parallel plate flow chamber and superfused with 2 ϫ 10 5 /ml bis-carboxyethyl-carboxyfluorescein-acetoxymethyl ester (BCECF-AM, Molecular Probes, Eugene, Oreg.) -labeled macrophages. Adhesion was determined in 15 high-power fields of 1.5 mm 2 each of the coverslip as described elsewhere (21) . fEnd.5 were treated for 6 h with 20% plasma in DMEM (0.1 U heparin/ml) or ␤VLDL fractions (50 g/ml in HBSS/1% bovine serum albumin/1.2 mmol/l Ca 2 ϩ ) at 37°C.
Ca
2؉ measurements
Cytosolic Ca 2ϩ was assayed as described previously (22) . Cells were loaded with Fluo-3-AM and baseline fluorescence was recorded after washing. Inhibitors [WEB 2086, 10 M (Boehringer, Mannheim, Germany) and HDL 100 g/ml apo AI] were added, followed by ␤VLDL. Fluorescence was measured confocally using a Meridian Insight microscope (Meridian, Okemos, Mich.) and an S-plan APO 60x (NA1.4) oil immersion lens (Olympus, Tokyo, Japan). An oscillating slit-shaped 488 nm light beam was used for excitation. Emission was measured at 530 nm, recorded on videotape, and normalized to baseline fluorescence after background correction.
Real time rtPCR for ICAM-1, VCAM-1, and HPRT
First strand cDNA generated from 10 ng total thoracic aorta RNA was subjected to quantitative real time reverse transcriptase-polymerase chain reaction (rtPCR) according to the suppliers protocol (Perkin-Elmer, Zaventem, Belgium). Oligonucleotides used as forward primer (F), reverse primer (R), and probes (P) labeled with the fluorescent quencher TAMRA (3Ј) and the indicator dye FAM (5Ј) were: for ICAM-1: F: 5Ј-TGATCCCT-GGGCCTGGT-3Ј; R: 5Ј-TTTCAGCCACTGAGTCTCCAAG-3Ј; P: 5Ј-FAM-CTCATGCAAGGAGGACCTCAGCCTG-TAMRA-3Ј; for VCAM-1: F: 5Ј-GTATCACGTGG ACATCTACTCTTTC C-3Ј; R: 5Ј-CTGTCTGTTCATGAGCTGGTCAC-3Ј; P: 5Ј-FAM-TGACCG-TGACCGGCTTCCCAAAC-TAMRA-3Ј. The copy numbers were calculated from plasmid cDNA standards containing the rtPCR amplicon. ICAM-1 and VCAM-1 levels were expressed as copy number per 1000 copies of hypoxanthine transferase (HPRT). HPRT oligonucleotides were: F: 5Ј-TTATCAGACTGAAGAGC-TACTGTAATGATC-3Ј; R: 5Ј-TTACC AGTGTCAATTATATCT-TCAACAATC-3Ј; P: 5Ј-JOE-TGAGAGATCATCTCCACCAATA-ACT TTTATGTCCC-TAMRA-3Ј
Determination of MDA-LDL auto-antibodies
Auto-antibodies against oxidized LDL in mice were determined as described earlier (23, 24) . Ninety six-well ELISA plates were coated with in vitro MDA-modified human LDL or native LDL overnight and blocked with 1% bovine serum albumin. Plasma samples were added at serial dilutions from 1:10 until 1:100 and incubated for 2 h. Plates were washed and a horseradish peroxidase-conjugated rabbit anti-mouse IgG was added. After developing, the absorbance was read at 492 nm. Auto-antibody levels are expressed as MDA-LDL/ native LDL ratio to account for unspecific binding to unmodified human LDL.
Adenoviral gene transfer of human PAF-acetylhydrolase
Recombinant adenovirus (AdPAF-AH) containing the cytomegalovirus promoter/enhancer and the human PAF-AH cDNA was generated by cotransfecting rescue plasmid pJM17 and shuttle plasmid pLpA containing the human PAF-AH cDNA into 293 cells (25) . PAF-AH cDNA was a gift from Dr P. Kolkhof (Bayer Pharma, Wuppertal, Germany). 5 ϫ 10 8 plaque-forming units (pfu) of either AdPAF-AH or AdRR5 control virus were injected i.v. in apoE Ϫ/Ϫ mice. Citrated blood was drawn from the retrobulbar plexus on indicated days. PAF-AH activity was assessed as described (26) .
Statistical methods
Nonparametric Kruskal-Wallis testing compared results of macrophage homing, ex vivo adhesion and Ca 2ϩ amplitudes. Individual differences were identified by Mann-Whitney-U or, where required, by Dunnett's test to correct for multiple testing. Responding cell fractions in the Ca 2ϩ experiments were compared by 2 test, followed by Fisher's Exact test for individual differences. A P value Ͻ 0.05 was considered significant. InStat V2.05 was used (Graphpad Software, San Diego, Calif.).
RESULTS
Cholesterol levels
ApoE
Ϫ/Ϫ and apoE
/AI ϩ/ϩ mice in the colony (6) on normal chow were not different with respect to non-HDL cholesterol levels (580Ϯ25 mg/dl and 610Ϯ30 mg/dl, nϭ6/10, Pϭns). Circulating human apo AI (240Ϯ19 mg/dl) led to an increase of HDL cholesterol to 105 Ϯ 3.5 mg/dl in apoE
HDL effect on macrophage homing
Peritoneal macrophages displayed typical leukocyte homing patterns as described previously (16) . Macrophages injected i.p. or subcutaneously into C57BL/6 mice displayed active trafficking. Cells migrated along the lymphatic vessels, homed to the lungs, and subsequently to liver and spleen (Fig. 1a, b) . When injected i.v., 235 Ϯ 37 (nϭ13) macrophages were found in the aortic root of 6-month-old apoE Ϫ/Ϫ mice (Fig. 1f ) . In 3-month-old apoE
, similar numbers of macrophages were counted (nϭ8, Pϭns). In C57BL/6 mice, 37-fold fewer macrophages homed (nϭ6, PϽ0.0001, Fig. 1f ). Lesion areas in the aortic roots of apoE Ϫ/Ϫ were 72,400 Ϯ 996 m 2 at 3 months and fourfold larger at 6 months (PϽ0.001, Fig. 1g ). These data indicated that macrophage homing is independent of lesion size. In 6 month apoE
, lesion areas were similar to those in 3 month apoE Ϫ/Ϫ mice (Fig.  1g ), but macrophage homing was threefold reduced in comparison to both 3 month and 6 month apoE Ϫ/Ϫ mice (nϭ8, PϽ0.01, Fig. 1f ). The fraction of lesion surface area immunoreactive for macrophages was 13 Ϯ 1.7% in apoE Ϫ/Ϫ /AI ϩ/ϩ (nϭ4) and 2.0-and 1.7-fold larger in 3 month and 6 month apoE Ϫ/Ϫ mice (nϭ6/7, PϽ0.01, Fig. 1h ), respectively.
Ex vivo macrophage adhesion is induced by apoE
؊/؊ plasma and ␤VLDL
To elucidate the mechanism of the reduction of macrophage homing in apoE Ϫ/Ϫ /AI ϩ/ϩ mice, adhesion of peritoneal macrophages to fEND.5 cells was studied in a flow chamber at a shear rate of 400s
Ϫ1
. Macrophages rolled on the endothelium before adhering firmly (Fig. 2a) . When fEnd.5 cells were exposed to apoE Ϫ/Ϫ plasma prior to superfusion, 3.7-fold more adhesion (nϭ5, PϽ0.05) was observed compared to C57BL/6 plasma whereas apoE Ϫ/Ϫ /AI ϩ/ϩ plasma induced a nonsignificant 1.7-fold increase (nϭ5, Fig. 2b) . ␤VLDL from apoE Ϫ/Ϫ plasma increased adhesion 4.9-fold over C57BL/6 ␤VLDL (nϭ5, PϽ0.001, Fig. 2c ). Palmitoyllysophosphatidylcholine (p-LPC) increased macrophage adhesion 5.5-fold compared to vehicle control or C57BL/6 plasma (nϭ5, PϽ0.001, Fig. 2d ). ApoE Ϫ/Ϫ ␤VLDL or p-LPC-induced adhesion was reduced 3-fold or 3.4-fold by apoE Ϫ/Ϫ /AI ϩ/ϩ HDL (nϭ5, PϽ0.01, Fig. 2c, d ) whereas apoE Ϫ/Ϫ HDL fractions had no inhibitory effect (Fig. 2c) . PAF receptor antagonist WEB2086 blocked ␤VLDL or p-LPC-induced adhesion (nϭ5, PϽ0.01, Fig. 2c, d ). In contrast, human rTNF␣-induced adhesion was not affected by WEB2086, suggesting that both ␤VLDL and p-LPC, in contrast to TNF-␣, induced lesions whereas older apoE Ϫ/Ϫ had fourfold larger lesions. h) Endogenous macrophages were occupying less area of the lesions in apoE Ϫ/Ϫ / AI ϩ/ϩ mice compared to apoE Ϫ/Ϫ mice.
macrophage adhesion through a PAF-sensitive pathway (Fig. 2d) .
HDL reduces ␤VLDL triggered cytosolic Ca
2؉ signaling
In fEND.5 monolayers, ␤VLDL elicited biphasic cytosolic Ca 2ϩ transients consisting of a rapid early peak within 150 s after stimulation and a sustained component within 10 to 15 min (Fig. 3a-c) /82 cells, PϽ0.0001, Fig. 3d) . The concentration required to induce Ca 2ϩ signaling in 50% of the cells was 87 g/ml for apoE (16%, nϭ60, PϽ0.0001, Fig. 3d) . Thus, PAFlike activity in oxidatively modified ␤VLDL elicits cytosolic Ca 2ϩ signaling. 
HDL reduces adhesion molecule expression ex vivo and in vivo
Expression of VCAM-1 and ICAM-1 was studied at the transcriptional and functional level ex vivo and in vivo. rtPCR on total RNA purified from the thoracic aorta detected 2.68 Ϯ 1.26 copies of ICAM-1 per 1000 copies of HPRT in apoE Ϫ/Ϫ mice, but only 0.38 Ϯ 0.2 copies in apoE Ϫ/Ϫ /AI ϩ/ϩ mice (nϭ8, PϽ0.05). VCAM-1 expression was also 2.7-fold lower in apoE PϽ0.05, Fig. 3e) . As an estimate for expression of functional ICAM-1 and VCAM-1 protein, in vivo blocking studies were carried out in the two strains of mice. VCAM-1 inhibition reduced macrophage homing to apoE Ϫ/Ϫ aortas by 48% (nϭ5, PϽ0.05), whereas blocking of both VCAM-1 and ICAM-1 reduced homing by 75% (nϭ5, PϽ0.05, Fig. 3f ). In contrast, blocking of VCAM-1 and ICAM-1 did not reduce in vivo macrophage homing in apoE (Fig. 3f) .
To verify that apoE
/AI ϩ/ϩ ␤VLDL was less potent to induce ICAM-1 and VCAM-1 expression, ex vivo blocking studies were carried out. In the flow chamber, anti-ICAM-1 and -VCAM-1 mAbs elicited a dose-dependent inhibition of macrophage adhesion induced by apoE Ϫ/Ϫ plasma (not shown). At plateau concentrations of the combined antibodies, a 3.4-fold inhibition of macrophage adhesion was obtained with apoE Ϫ/Ϫ plasma-stimulated fEnd.5, whereas the 3-fold reduced adhesion in response to apoE Ϫ/Ϫ /AI ϩ/ϩ was further reduced 4.7-fold (nϭ4, PϽ0.05, Fig. 3g) . Separately, ICAM-1 and VCAM-1 accounted for 48% and 39% of ex vivo adhesion in response to apoE Ϫ/Ϫ plasma (nϭ4, PϽ0.01) and for 8% and 53% of the reduced adhesion observed in response to apoE Ϫ/Ϫ /AI ϩ/ϩ plasma (nϭ4, PϽ0.05, VCAM-1 vs. control, Fig. 3g) . Thus, reduced endothelial adhesiveness in apoE Ϫ/Ϫ /AI ϩ/ϩ mice is attributable to a greater reduction of ICAM-1 than VCAM-1 expression.
HDL decreases oxidative stress in apoE ؊/؊ mice
The ratio of antibodies against oxidatively modified LDL over antibodies recognizing human native LDL were 7.7 Ϯ 3.4 in apoE Ϫ/Ϫ plasma compared to 4.9 Ϯ 1.4 in apoE Ϫ/Ϫ /AI ϩ/ϩ plasma (nϭ12, PϽ0.01), indicating a decrease of immunogenic neoepitopes in ␤VLDL when high levels of HDL were present.
Breakdown of PAF-like compounds in vivo reduces macrophage adhesion ex vivo and in vivo
In apoE Ϫ/Ϫ mice, liver-directed PAF-AH gene transfer induced a 1.5-fold increase in PAF-AH plasma activity (nϭ13, PϽ0.0001, day 0 vs. 7, Fig. 4a ). AdRR5 did not induce an increase in PAF-AH plasma activity (23.5Ϯ1.6 vs. 25.2Ϯ2 AU, day 0 vs. 7, nϭ4). AdRR5-␤VLDL induced 3.5-fold more macrophage adhesion (nϭ5, PϽ0.01, Fig. 4b ) than AdPAF-AH-␤VLDL. Compared to AdRR5, AdPAF-AH reduced macrophage homing in apoE Ϫ/Ϫ mice 2.6-fold (PϽ0.02, nϭ6/13, Fig. 4c ).
DISCUSSION
In this study, high levels of human-like HDL decreased endothelial adhesion molecule expression in apoE Ϫ/Ϫ mice. This was due to diminished oxidative modification of ␤VLDL leading to decreased macrophage accumulation. Gene transfer of PAFacetylhydrolase reduced ex vivo macrophage adhesion and in vivo homing without changing HDL levels. Thus, the inhibitory effect of HDL on macro- phage homing was apparently independent of the function of HDL as a cholesterol acceptor.
Previously, the antiadhesive effect of HDL has been well established in vitro (8) . However, using the same mouse model in the prelesion state, Dansky et al. did not observe reduced VCAM-1 expression or recruitment of mononuclear cells by immunohistochemistry (27) . We find in slightly more advanced apoE Ϫ/Ϫ lesions than studied by Dansky and colleagues that less endogenous macrophages accumulate in lesions of mice with high levels of human-like HDL. These data agree with previous reports on apoE Ϫ/Ϫ mice (28) . In our study, reduced macrophage content as established in the functional in vivo homing assay is due to reduced endothelial adhesiveness. This conclusion is supported by quantitative rtPCR data at the mRNA and by functional blocking studies for adhesion molecules at the protein level. Differences in the outcome of the studies are potentially due to the different time points chosen for the investigation since subtle differences in the dynamic state of a lesion will be harder to detect in younger mice.
Our study demonstrates that in vivo oxidative modification of atherogenic lipoproteins (in the mouse, predominantly ␤VLDL) is responsible for increased leukocyte homing in apoE Ϫ/Ϫ mice. ApoE Ϫ/Ϫ ␤VLDL-associated compounds with PAFlike bioactivity (29) induced cytosolic Ca 2ϩ signaling through a PAF-sensitive pathway leading to VCAM-1 and ICAM-1 expression. Overexpression of human apo AI (4) in apoE Ϫ/Ϫ mice results in an increase of HDL causing breakdown of ␤VLDL-associated PAFlike bioactivity. Autoantibodies against modified lipoproteins in apoE Ϫ/Ϫ plasma, as a measure for the in vivo oxidation of ␤VLDL, were reduced by humanlike HDL reducing its potency to induce ex vivo cytosolic Ca 2ϩ signals. This blunted in vivo and ex vivo expression of ICAM-1 and VCAM-1. These findings suggest that HDL may exert its antiatherogenic effect by antagonizing oxidation of lipoproteins that are associated with cardiovascular disease and inversely correlated to HDL-C in humans (11) . In vitro, accumulation of proadhesive PAF-AH substrates in atherogenic lipoproteins and the protective effect of HDL have been demonstrated (14, 29) . The antioxidative effect of HDL has been attributed to paraoxonase and PAF-AH circulating with the mature lipoprotein particle (9, 10) . ApoE Ϫ/Ϫ -HDL-associated PAF-AH activity indeed is markedly increased in apo AI transgenics (B. De Geest et al., unpublished results), suggesting that increasing HDL concomitantly increases the antioxidative capacity of PAF-AH.
Ex vivo, the effect of apo E Ϫ/Ϫ -␤VLDL was essentially entirely due to PAF-like bioactivity, as indicated by the nearly complete inhibition of Ca 2ϩ signals and macrophage adhesion in the presence of the PAF receptor antagonist WEB2086. This suggests that the loss of macrophage adhesion in response to ␤VLDL isolated from AdPAF-AH-treated mice compared to the control virus treated mice is due to reduced accumulation of PAF-like bioactivity in ␤VLDL. Beyond that, increases of PAF-AH also diminished macrophage homing in vivo. Additional studies are needed to establish reduction of lesion formation by PAF-AH gene transfer in vivo. Compared to strategies directed at elevating circulating apo AI, which requires much higher viral doses (25, 30) , a 1.5-fold increase in PAF-AH activity as achieved in this study using 5 ϫ 10 8 pfu of AdPAF-AH was sufficient to significantly reduce macrophage homing.
Mutations in the PAF-AH gene are independent risk factors for coronary artery disease (31) , and low levels of PAF-AH are found in myocardial infarction (32) , suggesting that our findings in apoE Ϫ/Ϫ mice are reflecting human pathophysiology.
Taken together, our results suggest that if HDL levels are low PAF-like bioactivity accumulates in proatherogenic lipoprotein particles. It is this bioactivity that ultimately leads to endothelial activation and monocyte recruitment (Fig. 5) . Increasing HDL levels allows breakdown of these PAF-like compounds by the associated increase of PAF-AH activity (Fig. 5) . Increasing PAF-AH activity without affecting HDL-levels significantly reduced endothelial adhesiveness and macrophage recruitment to lesion prone sites, suggesting that in apoE Ϫ/Ϫ mice raising HDL may be antiatherogenic through the concomitant increase of antioxidative capacity conveyed by PAF-AH (Fig. 5) .
In conclusion, our study establishes the relation between HDL-associated PAF-AH, prevention of oxida- Figure 5 . Schematic representation of the antiatherogenic effect of HDL-associated PAF-AH. PAF-like compounds accumulate in proatherogenic lipoproteins with low HDL levels (center). Raising HDL levels (left panel) induces a concomitant increase in PAF-AH activity to break down PAF-like bioactivity. When PAF-AH activity is increased without altering HDL levels (right panel), PAF-AH still associates with HDL particles, increases its antioxidative capacity, and breaks down oxidation products contained in proatherogenic lipoproteins.
tion of atherogenic lipoproteins, and macrophage homing, which is the initial step in atherogenesis. PAF-AH gene transfer is a very promising therapeutic strategy to abolish the oxidation of atherogenic lipoproteins in vivo. These data suggest that even if means to increase HDL levels are not available, the quality of the HDL particles can be improved dramatically. Further studies to evaluate the clinical effect of reducing oxidative stress by modulating the antioxidative potential of HDL are warranted. 
